Exhibit 10.2

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this IP Agreement) is made as of the 15thday of April, 2008 by
and between CV THERAPEUTICS, INC., a Delaware corporation (Grantor), and TPG-AXON ROYALTY TRUST, a trust established under the laws of the Republic of Ireland (Secured Party).

RECITALS

Grantor has agreed to sell the right to receive certain payments to Secured Party (the Royalty) based on sales of Regadenoson, the chemical name and structure of which are set forth on Exhibit A attached
hereto (Regadenoson), pursuant to a certain Asset Sale and Purchase Agreement dated as of April 10, 2008 between Grantor and Secured Party, as amended from time to time (as amended, the Purchase
Agreement). The closing of the transactions contemplated by the Purchase Agreement is contingent upon the execution and delivery of this IP Agreement. Secured Party is willing to enter into the Purchase Agreement with Grantor, but only
upon the condition, among others, that Grantor shall grant to Secured Party a security interest in certain patents, patent applications and other assets, to secure the payment and performance of Grantors obligations under the Purchase
Agreement and the other Transaction Documents. Defined terms used but not defined herein shall have the same meanings as in the Purchase Agreement.

AGREEMENT

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby
acknowledged and intending to be legally bound, Grantor hereby represents, warrants, covenants and agrees as follows:

Effective as
of the Closing Date, Grantor does hereby grant to Secured Party a continuing security interest of first priority in all of Grantors right, title and interest in, to and under the following registered and unregistered intellectual property
collateral, whether now or hereafter existing, and any and all proceeds thereof, as security for the prompt and complete payment and performance of all of Grantors obligations now or hereafter existing under the Purchase Agreement, this IP
Agreement, and the other Transaction Documents (all of which shall collectively be called the Intellectual Property Collateral):

(a) All Licensed Patents in the Territory set forth on Exhibit B attached hereto and any Licensed Patents in the Territory
issued after the date of this Agreement (the Patents);

(b) All Licensed Know-How in the
Territory;

(c) All licenses or other rights to use any of the Licensed Patents in the Territory, including, without
limitation, the licenses under the Astellas Agreement (collectively, the Licenses);

(d) Any and
all claims and causes of action for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the
intellectual property rights identified above;



1.



---

(e) All amendments, extensions, renewals and extensions of any of the Patents or the
Licenses;

(f) The CVT Royalty Interest; and

(g) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty
payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to Secured
Party under the Purchase Agreement. Upon the occurrence and during the continuance of a CVT Event of Default, Secured Party shall have the right to exercise all the remedies of a secured party under the Code. Grantor will pay any expenses (including
reasonable attorneys fees) incurred by Secured Party in connection with the exercise of any of Secured Partys rights hereunder, including without limitation any expense incurred in disposing of the Intellectual Property Collateral. All
of Secured Partys rights and remedies with respect to the Intellectual Property Collateral shall be cumulative.

Grantor represents
and warrants that Exhibit B attached hereto sets forth any and all intellectual property rights in connection with which Grantor has registered or filed a patent application with the United States Patent and Trademark Office with respect to
Regadenoson.

The provisions of this IP Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns. Neither this IP Agreement nor any rights or obligations hereunder may be assigned, sold or otherwise disposed of or transferred in whole or in part by any party, by operation of law or otherwise, without the prior
written consent of the other party, except in accordance with the terms of Section 9.6 of the Purchase Agreement in the same manner as a permitted assignment of some or all of a partys rights and/or obligations under the Purchase
Agreement.

This IP Agreement shall be governed by and construed, interpreted and enforced in accordance with the laws of the State of New
York, as applied to agreements executed and performed entirely in New York, without giving effect to the principles of conflicts of law thereof other than Section 5-1401 of the General Obligations Law of the State of New York.

[Signature pages follow.]



2.



---

IN WITNESS WHEREOF, the parties have caused this IP
Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.



|                      |  |                                 |  |                                                    |  |                                                               |  |                                       
|--------------------- |  | ------------------------------- |  | -------------------------------------------------- |  | ------------------------------------------------------------- |  | --------------------------------------
|GRANTOR:              |  |                                 |  | SECURED PARTY:                                    
|                      |  |                                
|CV THERAPEUTICS, INC. |  |                                 |  | PFPC BANK LIMITED                                 
|                      |  |                                 |  | in its sole capacity as trustee, and on behalf, of
|                      |  |                                 |  | TPG-AXON ROYALTY TRUST,                           
|By:                   |  | Louis G. Lange                  |  |                                                    |  | a trust established under the laws of the Republic of Ireland
|                      |  |                                 |  |                                                    |  |                                                              
|Print Name:           |  | Louis G. Lange, M.D., Ph.D.     |  |                                                    |  |                                                              
|Title:                |  | Chairman of the Board and Chief |  |                                                    |  |                                                              
|                      |  | Executive Officer               |  |                                                    |  |                                                              
|                      |  |                                 |  |                                                    |  | By:                                                           |  | Paul Halley                           
|                      |  |                                 |  |                                                    |  | Name:                                                         |  | Paul Halley                           
|                      |  |                                 |  |                                                    |  | Title:                                                        |  | Head of Trustee and Custodial Services



3.



---

EXHIBIT A

REGADENOSON

LOGO

known as (1-{9-[(4S, 2R, 3R,
5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, and identified by the Chemical Abstracts Service Registry Number 313348-27-5.



4.



---

EXHIBIT B

LICENSED PATENTS



|                                  |  |                   |  |                          |  |                                                                             
|--------------------------------- |  | ----------------- |  | ------------------------ |  | ----------------------------------------------------------------------------
|Country                           |  | Application No.   |  | Patent / Publication No. |  | Title                                                                       
|Patent Cooperation Treaty (PCT) |  | PCT/US00/40281    |  | WO 00/78779 A2           |  | N-PYRAZOLE A2ARECEPTOR AGONISTS                                             
|                                  |  |                   | 
|PCT                               |  | PCT/US00/17095    |  | WO 00/78778 A2           |  | C-PYRAZOLE A2ARECEPTOR AGONISTS                                             
|                                  |  |                   | 
|PCT                               |  | PCT/US01/05831    |  | WO 01/62979 A2           |  | METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A2ARECEPTOR                   
|                                  |  |                   | 
|PCT                               |  | PCT/US03/23511    |  | WO 2004/011010 A1        |  | MYOCARDIAL PERFUSION IMAGING USING A2ARECEPTOR AGONISTS                     
|                                  |  |                   | 
|PCT                               |  | PCT/US04/002304   |  | WO 2005/082379 A1        |  | MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS              
|                                  |  |                   | 
|PCT                               |  | PCT/US2005/037368 |  | WO 2006/044856 A2        |  | USE OF A2AADENOSINE RECEPTOR AGONISTS                                       
|                                  |  |                   | 
|PCT                               |  | PCT/US2007/003022 |  | WO 2007/092372 A1        |  | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS  
|                                  |  |                   | 
|United States                     |  | US 09/338,185     |  | US 6,403,567 B1          |  | N-PYRAZOLE A2AADENOSINE RECEPTOR AGONISTS                                   
|                                  |  |                   | 
|United States                     |  | US 10/018,446     |  | US 6,642,210 B1          |  | 2-(N-PYRAZOLO) ADENOSINES WITH APPLICATION AS ADENOSINE A2ARECEPTOR
AGONISTS
|                                  |  |                   | 
|United States                     |  | US 10/652,378     |  | US 7,183,264 B2          |  | N-PYRAZOLE A2ARECEPTOR AGONISTS                                             
|                                  |  |                   | 
|United States                     |  | US 11/252,760     |  | US 7,144,872 B2          |  | N-PYRAZOLE A2ARECEPTOR AGONISTS                                             
|                                  |  |                   | 
|United States                     |  | US 11/588,834     |  | US 2007/0203090 A1       |  | N-PYRAZOLE A2ARECEPTOR AGONISTS                                             
|                                  |  |                   | 
|United States                     |  | US 09/338,327     |  | US 6,214,807 B1          |  | C-PYRAZOLE A2ARECEPTOR AGONISTS                                             
|                                  |  |                   | 
|United States                     |  | US 09/812,176     |  | US 6,855,818 B2          |  | C-PYRAZOLE A2ARECEPTOR AGONISTS                                             
|                                  |  |                   | 
|United States                     |  | US 10/018,758     |  | US 6,770,634 B1          |  | C-PYRAZOLE A2ARECEPTOR AGONISTS                                             
|                                  |  |                   | 
|United States                     |  | US 10/813,535     |  | US 7,109,180 B2          |  | C-PYRAZOLE A2ARECEPTOR AGONISTS                                             
|                                  |  |                   | 
|United States                     |  | US 11/522,120     |  | US 2007/0207978 A1       |  | C-PYRAZOLE A2ARECEPTOR AGONISTS                                             
|                                  |  |                   | 
|United States                     |  | US 11/070,768     |  | US 2005/0175535 A1       |  | MYOCARDIAL PERFUSION IMAGING METHOD                                         
|                                  |  |                   | 
|United States                     |  | US 10/629,368     |  | US 2004/0064039 A1       |  | MYOCARDIAL PERFUSION IMAGING METHOD                                         
|                                  |  |                   | 
|United States                     |  | US 10/766,403     |  | US 2005/0020915 A1       |  | MYOCARDIAL PERFUSION IMAGING METHODS AND COMPOSITIONS                       
|                                  |  |                   | 
|United States                     |  | US 11/253,322     |  | US 2006/0084625 A1       |  | USE OF A2AADENOSINE RECEPTOR AGONISTS                                       
|                                  |  |                   | 
|United States                     |  | US 11/701,699     |  | US 2007/0265445 A1       |  | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS  
|                                  |  |                   | 
|United States                     |  | US 11/750,295     |  | US 2007/0225247 A1       |  | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS  



5.



---

|              |  |                 |  |                          |  |                                                                                               
|------------- |  | --------------- |  | ------------------------ |  | ----------------------------------------------------------------------------------------------
|Country       |  | Application No. |  | Patent / Publication No. |  | Title                                                                                         
|United States |  | US 11/766,964   |  | US 2007/0299089 A1       |  | USE OF A2AADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA                            
|              |  |                 | 
|United States |  | US 11/848,743   |  | Not published            |  | METHODS AND COMPOSITIONS FOR INCREASING PATIENT TOLERABILITY DURING MYOCARDIAL IMAGING METHODS
|              |  |                 | 
|United States |  | US 11/864,437   |  | Not published            |  | METHODS FOR MYOCARDIAL IMAGING IN PATIENTS HAVING A HISTORY OF PULMONARY DISEASE              
|              |  |                 | 
|United States |  | US 11/969,047   |  | Not published            |  | MYOCARDIAL PERFUSION IMAGING                                                                  
|              |  |                 | 
|Canada        |  | CA2000002377746 |  | CA2377746 C              |  | N-PYRAZOLE A2ARECEPTOR AGONISTS                                                               
|              |  |                 | 
|Canada        |  | CA2000002375430 |  | CA2375430 C              |  | C-PYRAZOLE A2ARECEPTOR AGONISTS                                                               
|              |  |                 | 
|Canada        |  | CA2001002439222 |  | CA2439222AA              |  | METHOD OF IDENTIFYING PARTIAL AGONISTS OF THE A2ARECEPTOR                                     
|              |  |                 | 
|Canada        |  | CA2003002492855 |  | CA2492855AA              |  | MYOCARDIAL PERFUSION IMAGING USING A2ARECEPTOR AGONISTS                                       
|              |  |                 | 
|Canada        |  | CA2004002554169 |  | CA2554169AA              |  | MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS                                
|              |  |                 | 
|Canada        |  | CA2005002583185 |  | CA2583185AA              |  | USE OF A2AADENOSINE RECEPTOR AGONISTS                                                         
|              |  |                 | 
|Mexico        |  | MX2001PA0013325 |  | MX244944                 |  | N-PYRAZOLE A2ARECEPTOR AGONISTS                                                               
|              |  |                 | 
|Mexico        |  | MX2001PA0013350 |  | MX245023                 |  | C-PYRAZOLE A2ARECEPTOR AGONISTS                                                               
|              |  |                 | 
|Mexico        |  | MX2005PA0001123 |  | Only abstract published  |  | MYOCARDIAL PERFUSION IMAGING USING A2ARECEPTOR AGONISTS                                       
|              |  |                 | 
|Mexico        |  | MX2006PA008521  |  | Only abstract published  |  | MYOCARDIAL PERFUSION IMAGING USING ADENOSINE RECEPTOR AGONISTS                                
|              |  |                 | 
|Mexico        |  | MX2007PA004749  |  | Only abstract published  |  | USE OF A2AADENOSINE RECEPTOR AGONISTS                                                         



6.